PATENT CLAIM ANALYSIS

Application Number: 16025461
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["514", "225800"]

Abstract:
The present invention relates to compositions and methods for the treatment of neurological disorders related to glutamate excitotoxicity and Amyloid β toxicity. More specifically, the present invention relates to novel combinatorial therapies of Multiple Sclerosis, Alzheimer's disease, Alzheimer's disease related disorders, Amyotrophic Lateral Sclerosis, Parkinson's disease, Huntington's disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, or spinal cord injury.

Claim (Index 21):
The method of  claim 14 , wherein baclofen is administered in a dosage from about 0.15 to 15 mg per day.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 95.0
- Lexical Diversity: 1.61702
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14014650', '14914666', '13706907', '13691981', '14479614']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8467289447277221
- 35 USC 102 Novelty (BERT): 0.6880944789937722
- Combined Prediction Score: 0.8308654981543272
- Mean Citation Score: 658.991612
- Max Citation Score: 832.50775
- Similarity Product: 661.7391230043769

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test